aminoimidazole carboxamide has been researched along with Hematologic Malignancies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bontemps, F; Van den Berghe, G; Van Den Neste, E | 1 |
| Bouscary, D; Chapuis, N; Green, AS; Lacombe, C; Mayeux, P; Tamburini, J | 1 |
2 review(s) available for aminoimidazole carboxamide and Hematologic Malignancies
| Article | Year |
|---|---|
AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Clinical Trials as Topic; Enzyme Activation; Hematologic Neoplasms; Humans; Ribonucleosides | 2010 |
LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Hematologic Neoplasms; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Protein Serine-Threonine Kinases; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases | 2011 |